Whole genome sequencing studies applied to large populations or biobanks with extensive phenotyping raise new analytic challenges. The need to consider many variants at a locus or group of genes simultaneously and the potential to study many correlated phenotypes with shared genetic architecture provide opportunities for discovery and inference that are not addressed by the traditional one variant-one phenotype association study. Here we introduce a model comparison approach we refer to as MRP for rare variant association studies that considers correlation, scale, and location of genetic effects across a group of genetic variants, phenotypes, and studies. We consider the use of summary statistic data to apply univariate and multivariate gene-based meta-analysis models for identifying rare variant associations with an emphasis on protective protein-truncating variants that can expedite drug discovery. Through simulation studies, we demonstrate that the proposed model comparison approach can improve ability to detect rare variant association signals. We also apply the model to two groups of phenotypes from the UK Biobank: 1) asthma diagnosis, eosinophil counts, forced expiratory volume, and forced vital capacity; and 2) glaucoma diagnosis, intra-ocular pressure, and corneal resistance factor. We are able to recover known associations such as the protective association between rs146597587 in IL33 and asthma. We also find evidence for novel protective associations between rare variants in ANGPTL7 and glaucoma. Overall, we show that the MRP model comparison approach is able to retain and improve upon useful features from widely-used meta-analysis approaches for rare variant association analyses and prioritize protective modifiers of disease risk.
Introduction

1
Sequencing technologies are quickly transforming human genetic studies of complex 2 traits: it is increasingly possible to obtain whole genome sequence data on thousands of 3 samples at manageable costs. As a result, the genome-wide study of rare variants 4 (minor allele frequency [MAF] < 1%) and their contribution to disease susceptibility 5 and phenotype variation is now feasible [1] [2] [3] [4] . 6 In genetic studies of diseases or continuous phenotypes, rare variants are hard to 7 assess individually due to the limited number of copies of each rare variant. Hence, to 8 boost the ability to detect a signal, evidence is usually 'aggregated' across variants. 9 When designing an 'aggregation' method, there are three questions that are usually 10 considered. First, across which biological units should variants be combined; second, 11 which variants mapping within those units should be included [5] ; and third, which 12 statistical model should be used [6] ? Given the widespread observations of shared 13 genetic risk factors across distinct diseases, there is also considerable motivation to use 14 gene discovery approaches that leverage the information from multiple phenotypes 15 jointly. In other words, rather than only aggregating variants that may have effects on a 16 single phenotype, we can also bring together sets of phenotypes for which a single 17 variant or sets of variants might have effects.
18
In this paper, we present a Bayesian multiple rare variants and phenotypes (MRP) 19 model comparison approach for identifying rare variant associations as an alternative to 20 current widely-used statistical tests. The MRP framework exploits correlation, scale, or 21 location (direction) of genetic effects in a broad range of rare variant association study 22 designs including: case-control; multiple diseases and shared controls; single continuous 23 phenotype; multiple continuous phenotypes; or a mixture of case-control and multiple 24 continuous phenotypes (Fig 1) . MRP makes use of Bayesian model comparison, 25 whereby we compute a Bayes Factor (BF) defined as the ratio of the marginal 26 likelihoods of the observed data under two models: 1) a pre-specified null where all 27 genetic effects are zero; and 2) an alternative model where factors like correlation, scale, 28 or location of genetic effects are considered. The BF is an alternative to p-values from 29 traditional hypothesis testing. For MRP, the BF represents the statistical evidence for a 30 non-zero effect for a particular group of rare variants on the phenotype(s) of interest.
31
While many large genetic consortia collect both raw genotype and phenotype data, in 32 practice, sharing of individual genotype and phenotype data across groups is difficult to 33 achieve. To address this, MRP can take summary statistics, such as estimates of effect 34 cor(β snv1,trait1 ,β snv2,trait1 ) cor(β snv1,trait1 ,β snv1,trait2 ) R study β snv1,trait1,study2
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cor(β snv1,trait1,study1 ,β snv1,trait1,study2 ) β snv1,trait1,study1 in rare variant association analysis including the correlation matrices: R study (expected correlation of genetic effects among a group of studies), R var (expected correlation of genetic effects among a group of variants), and R phen (expected correlation of genetic effects among a group of phenotypes); the scale parameter for genetic variant annotation; and the location of genetic effects, which may be used to prioritize or identify protective modifiers of disease risk.
size and the corresponding standard error from typical single variant-single phenotype 35 linear or logistic regressions, as input data. Furthermore, we use insights from Liu et 36 al. [7] and Cichonska et al. [8] who suggest the use of additional summary statistics, like 37 covariance estimates across variants and studies, respectively, that would enable lossless 38 ability to detect gene-based association signals using summary statistics alone.
39
Aggregation techniques rely on variant annotations to assign variants to groups for 40 analysis. MRP allows for the inclusion of priors on the spread of effect sizes that can be 41 adjusted depending on what type of variants are included in the analysis. For instance, 42 protein truncating variants (PTVs) [9, 10] are an important class of variants that are 43 more likely to be functional because they often disrupt the normal function of a gene.
44
This biological knowledge can be reflected in the choices of priors for PTVs in MRP.
45
Since PTVs typically abolish or severely alter gene function, there is particular interest 46 in identifying protective PTV modifiers of human disease risk that may serve as targets 47 for therapeutics [11] [12] [13] data [5, 19] , otherwise zero correlation of genetic effects may be assumed, which is 98 used in dispersion tests like C-alpha [20, 21] and SKAT [14] ; and
99
• a K × K matrix R phen containing the correlations of genetic effects among 100 phenotypes, which may be obtained from common variant data [22] [23] [24] .
101
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The variance-covariance matrix of the effect sizes may be obtained from readily 102 available summary statistic data such as in-study LD matrices, effect size estimates (or 103 log odds ratios), and the standard errors of the effect size estimates (S1 Appendix). 
UK Biobank Data
147
GWAS Summary Statistics
148
We performed genome-wide association analysis using PLINK v2.00a(17 July 2017) as 149 previously described [15] . For asthma, we used the Firth fallback in PLINK, a hybrid 150 algorithm which normally uses the logistic regression code described in [29] , but 151 switches to a port of logistf()
152
(https://cran.r-project.org/web/packages/logistf/index.html) in two cases:
153
(1) one of the cells in the 2x2 allele count by case/control status contingency distribution properties of quadratic forms (S1 Appendix). As expected, an independent 221 effects model has high correlation with the gene-based test SKAT (r 2 = 0.99), whereas 222 the similar effects model has high correlation with the burden test (r 2 = 0.93, Fig 2A) . 223
Summary statistic data
224
To study the behavior of MRP using summary statistics we simulate two scenarios: first, 225 the scenario where analysts have access to all the raw genotype and phenotype data;
226
and second, the scenario where analysts only have access to summary statistics data [7] . 227 We conducted 1000 simulation experiments where we let K (the number of phenotypes) 228 = 3, M (the number of variants) = 10, S (the number of studies) = 2, N 0 (number of 229 individuals in study with access to all the data) = 10000, N 1 (meta-analysis study 1)
230
= 5000, N 2 (meta-analysis study 2) = 5000. improve ability to detect gene-based signals (Fig 2C) , and that considering prior mean 244 of genetic effects should aid in efforts to identify protective modifiers of disease risk
245
( Fig 2D) .
246
Applications
247
We applied the MRP model comparison approach to summary statistic data generated 248 from single variant logistic regression and linear regression analysis for coding variants 249
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on the UK Biobank array (Methods). We applied MRP separately to asthma and three 250 related traits as well as glaucoma and two related traits. We first applied MRP to GWAS summary statistics for asthma, eosinophil count, forced 254 expiratory volume in 1-second (FEV 1 ), and forced vital capacity (FVC) phenotypes.
255
Recent work has identified associations between the PTV rs146597587 in IL33 and 256 asthma and eosinophil counts [15, 16] . FEV 1 and FVC are measures of pulmonary 257 function that are used to diagnosis and classify pulmonary disease [35] . To demonstrate 258 the advantage of considering the phenotypes jointly, we applied MRP to rare missense 259 variants and PTVs (MAF < 1%) for each phenotype separately (Fig 3A-D) as well as to 260 all phenotypes jointly (Fig 3E,F) and obtained log 10 BF for each gene. We applied both 261 independent and similar effects models and used Bayesian model averaging to compute 262 a single BF per gene [36] . In agreement with previous studies, we observed evidence 263 that rare missense variants and/or PTVs in IL33 affect eosinophil counts and offer 264 protection from asthma from the single-phenotype analyses, though the evidence of 265 association was strongest for the joint analysis (S1 Table) [15, 16] . We performed an 266 analysis focused on identifying protective variants which also identified the IL33 267 association (Fig 3F) . The results were similar using only either the independent effects 268 (S3 Fig) or similar effects models (S4 Fig). We inspected the effect sizes from the 269 marginal GWAS regressions for the rare variants included in the analysis and found that 270 the association identified by MRP is likely driven by the PTV rs146597587 (Fig 3G) .
271
We also found moderate evidence for association between rare coding variants in 272 CCR3 and asthma. The log 10 BFs for CCR3 was 3.3 in the joint model compared to 273 only -0.5 in the asthma-only analysis (Fig 3, S1 Glaucoma, intra-ocular pressure, and corneal resistance factor
287
We also applied MRP to missense variants and PTVs for glaucoma, intra-ocular 288 pressure, and corneal resistance factor as well as performing joint analyses. Intra-ocular 289 pressure is a measure of the fluid pressure in the eye, is associated with glaucoma risk, 290 and has been linked to genetic variants associated with glaucoma [41] . Corneal 291 resistance factor is a measure of the cornea's ability to resist mechanical stress and has 292 been associated with glaucoma presence and severity [42] [43] [44] . While the individual 293 glaucoma analysis did not yield any associations with log 10 BF greater than three, the 294 joint analysis identified rare coding variants in both ANGPTL7 and WNT10A as 295 associated with glaucoma (Fig 4A-D Expression of ANGPTL7 is upregulated in glaucoma and has been proposed to 300 regulate intra-ocular pressure and glaucoma risk [45, 46] . The GWAS summary statistics 301 for the rare variants in ANGPTL7 suggest that the association with glaucoma is driven 302 by the missense variant rs28991009 that changes residue 175 from glutamine to histidine 303 (Fig 4F, G) . According to the HIPED protein expression database, ANGPTL7 protein 304 is expressed at ∼ 0.7 parts per million in vitreous humor, the material between the lens 305 and retina of the eyeball; in contrast, the expression of ANGPTL7 protein is less than 306 0.01 parts per million in 68 other normal tissues [31] . 
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Discussion 312
In this study, we developed a Bayesian model comparison approach MRP that shares 313 information across both variants and phenotypes to identify rare variant associations.
314
We used simulations to compare MRP to the widely used burden and SKAT tests for 315 identifying rare variant associations and found that jointly considering both variants 316 and phenotypes can improve the ability to detect associations. We also applied the 317 MRP model comparison framework to summary statistic data from two groups of traits 318 from the UK Biobank: asthma diagnosis, eosinophil counts, FEV 1 , and FVC; and 319 glaucoma diagnosis, intra-ocular pressure, and corneal resistance factor. We identified 320 strong evidence for the previously described association between the PTV rs146597587 321 in IL33 and asthma [15, 16] . We also found evidence for a link between rare variants in 322 ANGPTL7 and glaucoma, consistent with previous experiments that suggested a role 323 for ANGPTL7 in glaucoma [45, 46] . These results demonstrate the ability of the MRP 324 model comparison approach to leverage information across multiple phenotypes and 325 variants to discover rare variant associations.
326
As genetic data linked to high-dimensional phenotype data continues to be made 327 available through biobanks, health systems, and research programs, there is a large need 328 for statistical approaches that can leverage information across different genetic variants, 329 phenotypes, and studies to make strong inferences about disease-associated genes. Eosinophill count log10 BF < 2 2 log10 BF < 3 log10 BF > 3 
